Form 4: Rapport Therapeutics Director John Maraganore Granted 21,850 Stock Options

Rapport Therapeutics, Inc. Director John Maraganore has been granted 21,850 stock options with an exercise price of $10.95, aligning his interests with the company's future performance.

Summary

• John Maraganore, a Director of Rapport Therapeutics, Inc. (RAPP), was granted 21,850 stock options.
• The options have an exercise price of $10.95 per share.
• The transaction date for this grant was June 17, 2025.
• The options are set to expire on June 17, 2035.
• The shares underlying these options will vest upon the earlier of June 17, 2026, or the date of the next Annual Meeting of Stockholders of the Issuer, contingent on Mr. Maraganore's continued service.

Sentiment

Score: 6

Explanation: The grant of stock options to a director aligns their interests with shareholders, indicating confidence in the company's future performance and providing a positive signal of insider commitment.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, incentivizing long-term value creation.
• The exercise price of $10.95 indicates a specific valuation at the time of grant, providing a benchmark for future performance.

Future Outlook

The vesting schedule for the granted options, tied to continued service, indicates an expectation of the director's ongoing involvement and contribution to the company's strategic direction and performance through at least June 2026 or the next Annual Meeting of Stockholders.

Industry Context

Insider transactions, such as stock option grants to directors, are common practices in the biotechnology and pharmaceutical industries. They serve as a key component of executive and director compensation, aiming to align the interests of leadership with long-term shareholder value creation. This specific grant to a director of Rapport Therapeutics is consistent with typical compensation structures in the sector.

Comparison to Industry Standards

• The grant of stock options to a director is a standard practice for public companies, particularly in growth-oriented sectors like biotechnology, to incentivize long-term performance.
• The vesting schedule, tied to continued service, is a common mechanism to retain key personnel and ensure their commitment.
• The exercise price of $10.95 reflects the market valuation at the time of grant, which is typical for compensatory option grants.

Related Party Transactions

• The grant of 21,850 stock options to John Maraganore, a Director of Rapport Therapeutics, Inc., constitutes a transaction between the company and a related party.

Stakeholder Impact

• Shareholders: The option grant aligns the director's financial interests with shareholder value creation, potentially leading to more focused efforts on increasing the company's stock price.
• Employees: While not directly impacting all employees, such grants to leadership can signal stability and confidence in the company's future, potentially boosting morale.

Next Steps

• The granted stock options will vest upon the earlier of June 17, 2026, or the date of the next Annual Meeting of Stockholders, subject to the director's continued service.
• Following vesting, the director will have the right to exercise these options at the specified price of $10.95 per share until the expiration date of June 17, 2035.

Key Dates

Keywords

Rapport Therapeutics, RAPP, Stock Option, Director, Insider Transaction, Equity Grant, Form 4, Compensation, Vesting